Department of Dermatology, Gülhane School of Medicine, Ankara, Turkey.
J Dermatolog Treat. 2010 May;21(3):133-9. doi: 10.3109/09546630903266761.
With regard to the lack of effective treatment modalities for childhood localized vitiligo, the search for newer therapeutic agents continues.
To conduct an open, comparative trial to evaluate the clinical efficacy and safety of topical mometasone cream and pimecrolimus cream in the treatment of childhood vitiligo.
Fifty patients with childhood vitiligo were included in the study. Patients were treated for 3 months either with mometasone cream (0.1%) once daily or with pimecrolimus cream (1%) twice daily.
Forty patients, 20 from each group, completed the study. The two drugs were found to be statistically significantly effective for diminishing lesion size (Z = 3.070,p = 0.002 andZ = 3.845,p < 0.001, respectively). There were no statistical differences between the two drugs:Z = 1.427,p = 0.154 (mometasone non-inferiority to pimecrolimus). The mean repigmentation rate was 65% in the mometasone group and 42% in the pimecrolimus group at the end of therapy. Atrophy, telangiectasia and erythema were observed in two patients (10%) in the mometasone cream group and a burning sensation and pruritus were observed in two patients (10%) in the pimecrolimus cream group; drop-out was not related to the observed adverse effects.
Mometasone cream was found to be effective in the treatment of vitiligo on any part of the body. Pimecrolimus was not effective on the body except for the face in childhood localized vitiligo.
由于缺乏治疗儿童局限性白癜风的有效方法，因此仍在寻找新的治疗药物。
进行一项开放性、对照试验，评估莫米松乳膏和吡美莫司乳膏治疗儿童白癜风的临床疗效和安全性。
本研究纳入 50 例儿童白癜风患者。患者接受治疗 3 个月，分别每天使用一次莫米松乳膏（0.1%）或每天使用两次吡美莫司乳膏（1%）。
40 例患者（每组 20 例）完成了研究。两种药物在减少皮损面积方面均具有统计学显著疗效（Z = 3.070，p = 0.002 和 Z = 3.845，p < 0.001）。两种药物之间无统计学差异：Z = 1.427，p = 0.154（莫米松不劣于吡美莫司）。治疗结束时，莫米松组的平均复色率为 65%，吡美莫司组为 42%。莫米松乳膏组有 2 例（10%）患者出现萎缩、毛细血管扩张和红斑，吡美莫司乳膏组有 2 例（10%）患者出现烧灼感和瘙痒；脱落与观察到的不良反应无关。
莫米松乳膏对治疗身体任何部位的白癜风均有效。吡美莫司乳膏对面部以外的儿童局限性白癜风无效。
